{
  "abstract": "Background: The clinical efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy (± targeted agents) in patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) remains unclear. This study systematically evaluated the efficacy of this regimen.\n\nMethods: We searched PubMed, Web of Science, Embase, the Cochrane Library, and ClinicalTrials.gov for relevant randomized controlled trials (RCTs) published up to May 2026. The primary outcomes were progression-free survival (PFS) and overall survival (OS); effect sizes were estimated as hazard ratios (HRs) and 95% confidence intervals (95%CIs).\n\nResults: Six RCTs comprising 1,165 participants were included. The addition of PD-1/PD-L1 inhibitors to chemotherapy, with or without anti-VEGF agents, was associated with prolonged PFS (HR = 0.84, 95%CI [0.73, 0.95], P = 0.007) and OS (HR = 0.83, 95%CI [0.73, 0.94], P = 0.004). Subgroup analyses for PFS preliminarily suggested greater benefit in male patients (HR = 0.77, 95%CI [0.64, 0.94], P = 0.010), those with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (HR = 0.73, 95%CI [0.56, 0.95], P = 0.018), those with liver metastases (HR = 0.82, 95%CI [0.68, 0.98], P = 0.027), those without prior adjuvant therapy (HR = 0.81, 95%CI [0.67, 0.98], P = 0.030), those with a PD-L1 combined positive score (CPS) < 1 (HR = 0.53, 95%CI [0.30, 0.95], P = 0.032), those with synchronous metastases (HR = 0.79, 95%CI [0.63, 0.99], P = 0.037), and those with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (HR = 0.49, 95%CI [0.30, 0.80], P=0.005). These subgroup findings are exploratory, and interaction tests were not performed.\n\nConclusions: PD-1/PD-L1 inhibitors combined with chemotherapy (with or without targeted agents) may improve the prognosis of patients with pMMR mCRC and represent a potential first-line treatment option.\n\nSystematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261330186.",
  "abstract_shown": true,
  "affiliations": [
    "Department of General Surgery, Ningbo No.2 Hospital, Wenzhou Medical University",
    "The Fifth Clinical Medical College of Zhejiang Chinese Medical University",
    "The Second Clinical Medical College of Zhejiang Chinese Medical University",
    "Emergency Medical Center, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine"
  ],
  "article_type": "systematic review",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Sumin Lv"
    },
    {
      "affs": [
        1
      ],
      "name": "Chaoyue Ma"
    },
    {
      "affs": [
        1
      ],
      "name": "Zeqi Tang"
    },
    {
      "affs": [
        1
      ],
      "name": "Xinyan Zhang"
    },
    {
      "affs": [
        1
      ],
      "name": "Wen Shi"
    },
    {
      "affs": [
        2
      ],
      "name": "Shiyan Zhang"
    },
    {
      "affs": [
        2
      ],
      "name": "Minyuan Ni"
    },
    {
      "affs": [
        0
      ],
      "name": "Lihu Gu"
    },
    {
      "affs": [
        3
      ],
      "name": "Bangsheng Chen"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a290wnxs015fv.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1969514",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13730918/",
  "id": "a290wnxs015fv",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1969514/full",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Systematic Review"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7223154009",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1969514/pdf",
  "pmcid": "PMC13730918",
  "pmid": "42984586",
  "published": "2026-10-21",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/a290wnxs015fv.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1969514",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1969514/full"
    },
    {
      "first_seen": "2026-11-07T12:23:53Z",
      "native_id": "PMC13730918",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1969514"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "PD-1/PD-L1 inhibitors in the treatment of pMMR mCRC: a meta-analysis based on randomized controlled trials",
  "title_text": "PD-1/PD-L1 inhibitors in the treatment of pMMR mCRC: a meta-analysis based on randomized controlled trials",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T12:21:13Z",
  "url": "https://research.draconitic.com/paper/a290wnxs015fv",
  "venue": "Frontiers in Oncology",
  "versions": []
}